ZimVie Inc. (ZIMV) Q3 2024 Earnings Call Transcript Summary
ZimVie Inc. (ZIMV) Q3 2024 Earnings Call Transcript Summary
Adjusted EBITDA for Q3 2024 stood at $13.1 million, with an EBITDA margin of 12.7%.The following is a summary of the ZimVie Inc. (ZIMV) Q3 2024 Earnings Call Transcript:
以下是ZimVie Inc.（ZIMV）2024年第三季度業績會交易摘要：
Financial Performance:
金融業績：
Q3 2024 revenue was reported at $103 million, representing stability in the portfolio across implants, biomaterials, and digital solutions.
The company paid down $15 million in debt, achieving a gross debt of $220 million with a net balance of $153 million.
Adjusted EBITDA for Q3 2024 stood at $13.1 million, with an EBITDA margin of 12.7%.
ZimVie forecasts narrowed full-year revenue guidance to $450 million to $455 million and adjusted EBITDA to $60 million to $62 million.
2024年第三季度營業收入報告爲10300萬美元，代表種植物、生物材料和數字解決方案的投資組合穩定。
公司償還1500萬美元債務，實現22000萬美元總債務和淨平衡15300萬美元。
2024年第三季度調整後的EBITDA爲1310萬美元，EBITDA毛利率爲12.7%。
ZimVie預測將全年營業收入指導範圍調整爲45000萬至45500萬美元，調整後的EBITDA爲6000萬至6200萬美元。
Business Progress:
業務進展：
Enhanced manufacturing efficiency and decreased production costs.
Making strategic investments in sales teams, training programs, and digital dentistry symposia.
Incrementally investing in R&D to enhance the product portfolio.
Significant uptake seen in the U.S. launch of Gentech restorative components and the positive reception of new implant introductions.
提高了製造業效率並降低了生產成本。
在銷售團隊、培訓計劃和數字牙科學術會議上進行戰略性投資。
逐步增加對研發的投資，以完善產品組合。
在美國推出Gentech修復元件以及新種植體產品的受歡迎程度顯著增加。
Opportunities:
機會：
ZimVie anticipates benefiting from a lower interest rate environment in the U.S., potentially driving growth in dental implant procedures.
Continues to enhance its digital portfolio, fostered by the adoption of RealGUIDE 5.4 software and partnership with Medit, which are contributing to a significant growth in its digital offerings.
ZimVie預計將受益於美國較低的利率環境，可能推動牙科種植手術的增長。
繼續加強數字產品組合，通過採用RealGUIDE 5.4軟件和與Medit的合作，促成數字產品的顯著增長。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
